Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own diagnostic assays. This segment also manufactures the AffiDX SARS-CoV-2 rapid antigen lateral flow tests and supplies Affimer reagents for integration into other companies' products. Concurrently, the Therapeutics division focuses on advancing innovative cancer immunotherapies, strategically combining Avacta's proprietary technologies. Avacta has forged a variety of key partnerships and collaborations. These include a research alliance concerning its pre|CISION technology, which utilizes a substrate engineered for cleavage by fibroblast activation protein alpha; a drug development collaboration with LG Chem Life Sciences; a joint venture with Tufts University School of Medicine to progress Affimer drug conjugate therapies; a licensing deal with POINT Biopharma Inc. for the development of tumour-activated radiopharmaceuticals; and a drug development alliance with AffyXell to engineer mesenchymal stem cells for the treatment of autoimmune diseases.
—
Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own diagnostic assays. This segment also manufactures the AffiDX SARS-CoV-2 rapid antigen lateral flow tests and supplies Affimer reagents for integration into other companies' products. Concurrently, the Therapeutics division focuses on advancing innovative cancer immunotherapies, strategically combining Avacta's proprietary technologies. Avacta has forged a variety of key partnerships and collaborations. These include a research alliance concerning its pre|CISION technology, which utilizes a substrate engineered for cleavage by fibroblast activation protein alpha; a drug development collaboration with LG Chem Life Sciences; a joint venture with Tufts University School of Medicine to progress Affimer drug conjugate therapies; a licensing deal with POINT Biopharma Inc. for the development of tumour-activated radiopharmaceuticals; and a drug development alliance with AffyXell to engineer mesenchymal stem cells for the treatment of autoimmune diseases.
—
Daily adjusted close
Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own diagnostic assays. This segment also manufactures the AffiDX SARS-CoV-2 rapid antigen lateral flow tests and supplies Affimer reagents for integration into other companies' products. Concurrently, the Therapeutics division focuses on advancing innovative cancer immunotherapies, strategically combining Avacta's proprietary technologies. Avacta has forged a variety of key partnerships and collaborations. These include a research alliance concerning its pre|CISION technology, which utilizes a substrate engineered for cleavage by fibroblast activation protein alpha; a drug development collaboration with LG Chem Life Sciences; a joint venture with Tufts University School of Medicine to progress Affimer drug conjugate therapies; a licensing deal with POINT Biopharma Inc. for the development of tumour-activated radiopharmaceuticals; and a drug development alliance with AffyXell to engineer mesenchymal stem cells for the treatment of autoimmune diseases.